MaxCyte (NASDAQ:MXCT – Get Rating) and bioAffinity Technologies (NASDAQ:BIAF – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
Analyst Ratings
This is a summary of recent ratings and recommmendations for MaxCyte and bioAffinity Technologies, as reported by MarketBeat.
Get MaxCyte alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
| bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
MaxCyte currently has a consensus target price of $9.00, suggesting a potential upside of 63.93%. Given MaxCyte's higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than bioAffinity Technologies.
Profitability
This table compares MaxCyte and bioAffinity Technologies' net margins, return on equity and return on assets.| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -56.29% | -9.12% | -8.21% |
| bioAffinity Technologies | N/A | N/A | N/A |
Valuation & Earnings
This table compares MaxCyte and bioAffinity Technologies' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.89 million | 16.56 | -$19.08 million | ($0.23) | -23.87 |
| bioAffinity Technologies | N/A | N/A | -$6.33 million | N/A | N/A |
bioAffinity Technologies has lower revenue, but higher earnings than MaxCyte.
Insider and Institutional Ownership
66.7% of MaxCyte shares are owned by institutional investors. Comparatively, 2.4% of bioAffinity Technologies shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
MaxCyte beats bioAffinity Technologies on 5 of the 9 factors compared between the two stocks.
About MaxCyte
(Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
About bioAffinity Technologies
(Get Rating)
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.